查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1597837

TNF 抑制剂市场：按产品、按应用划分 - 2025-2030 年全球预测

TNF Inhibitors Market by Product (Biosimilars, Cimzia, Enbrel), Application (Ankylosing Spondylitis, Crohn's Disease, Hidradenitis Suppurativa) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年TNF抑制剂市值为338.4亿美元，预计2024年将达到361.5亿美元，复合年增长率为6.92%，到2030年将达到540.6亿美元。

TNF 抑制剂（肿瘤坏死因子抑制剂）是一种用于抑制发炎和阻止自体免疫疾病（如类风湿性关节炎、干癣和发炎性肠道疾病）疾病进展的药物。其应用既具有治疗性又具有预防性，透过抑制发炎细胞激素TNF 来缓解患者的症状。对 TNF 抑制剂的需求源于其在慢性发炎和自体免疫疾病治疗中的重要作用，这些疾病可能严重影响生活品质和生产力。 TNF 抑制剂的应用主要包括专门治疗这些疾病的製药公司和医疗保健提供者，最终用途包括医院、诊所和居家照护机构。影响市场的关键成长要素包括自体免疫疾病盛行率的上升、医疗保健支出的增加以及促进新配方开发的生物技术的发展。此外，生物疗法的广泛接受为市场扩张提供了新的机会。然而，高成本、生物相似药竞争和严格的监管要求等挑战构成了主要障碍。为了缓解这些障碍，人们越来越关注透过口服生技药品和奈米颗粒递送等创新技术来改善递送机制并减少副作用。最新的商机包括透过先进的基因研究和利用人工智慧的药物发现来促进个人化医疗和提高治疗效果。公司还可以探索向新兴市场进行地理扩张，这些市场的患者人数不断增长，但治疗选择有限。此外，可以透过加强病患教育和促进医疗保险覆盖合作来提高市场渗透率。儘管面临监管限制和竞争压力等挑战，但由于专注于未满足的医疗需求的策略创新，TNF抑制剂市场仍具有巨大的成长潜力。透过客製化解决方案来解决特定客户和患者的挑战，公司可以在这个动态的市场格局中建立一个引人注目的地位。

主要市场统计
基准年[2023] 338.4亿美元
预测年份 [2024] 361.5亿美元
预测年份 [2030] 540.6亿美元
复合年增长率（%） 6.92%

市场动态：揭示快速发展的 TNF 抑制剂市场的关键市场洞察

供需的动态交互作用正在改变 TNF 抑制剂市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 自体免疫疾病盛行率增加
    • 医疗支出的增加和诊断技术的发展
  • 市场限制因素
    • 与使用 TNF 抑制剂相关的不良健康影响和感染风险
  • 市场机会
    • 生物技术的进步、新型和改进的 TNF 抑制剂的开发
    • 扩大癌症等各种疾病治疗的应用
  • 市场问题
    • 自体免疫疾病替代治疗方案的可用性

波特五力：驾驭 TNF 抑制剂市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 TNF 抑制剂市场的外部影响

外部宏观环境因素在塑造 TNF 抑制剂市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解TNF抑制剂市场的竞争格局

对 TNF 抑制剂市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：TNF 抑制剂市场供应商的绩效评估

FPNV定位矩阵是评估TNF抑制剂市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製 TNF 抑制剂市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对 TNF 抑制剂市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 自体免疫疾病增加
      • 医疗费用的增加和诊断技术的发展
    • 抑制因素
      • 与使用 TNF 抑制剂相关的不良健康影响和感染风险
    • 机会
      • 生物技术的进步以及新型和改进的 TNF 抑制剂的开发
      • 扩大在癌症等各种疾病治疗的应用
    • 任务
      • 自体免疫疾病替代治疗方案的可用性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 TNF 抑制剂市场：副产品

  • 介绍
  • 生物相似药
  • Cimzia
  • Enbrel
  • Humira
  • Remicade
  • 辛波尼/辛波尼亚里亚

第七章 TNF 抑制剂市场：依应用分类

  • 介绍
  • 僵直性脊椎炎
  • 克隆氏症
  • 化脓性汗腺炎
  • 幼年特发性关节炎
  • 干癣
  • 干癣性关节炎
  • 类风湿性关节炎
  • 溃疡性大肠炎

第八章美洲TNF抑制剂市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太TNF抑制剂市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲TNF抑制剂市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Alkem Laboratories Ltd.
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb
  • Cadila Healthcare Ltd.
  • Cipla Ltd.
  • Dr Reddy's Laboratories Ltd.
  • Emcure Pharmaceuticals Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Intas Pharmaceuticals Ltd.
  • Janssen Pharmaceuticals
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd.
  • Macleods Pharmaceuticals Pvt. Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Ranbaxy Laboratories Limited
  • Reliance Life Sciences
  • Roche Products India Pvt Ltd.
  • Samsung Bioepis NL BV
  • Sanofi SA
  • Torrent Pharmaceuticals Ltd.
  • UCB Inc.
Product Code: MRR-2A0283E255AF

The TNF Inhibitors Market was valued at USD 33.84 billion in 2023, expected to reach USD 36.15 billion in 2024, and is projected to grow at a CAGR of 6.92%, to USD 54.06 billion by 2030.

TNF inhibitors, or tumor necrosis factor inhibitors, are a class of medications used to reduce inflammation and halt disease progression in autoimmune conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Their scope encompasses both therapeutic and prophylactic applications, providing relief to patients by inhibiting the pro-inflammatory cytokine TNF. The necessity of TNF inhibitors stems from their critical role in managing chronic inflammatory and autoimmune disorders that can severely impact the quality of life and productivity. The application of TNF inhibitors primarily spans pharmaceutical companies and healthcare providers specializing in the treatment of these ailments, with an end-use scope including hospitals, clinics, and home care settings. Key growth factors influencing the market include the rising prevalence of autoimmune diseases, increasing healthcare expenditure, and advancements in biotechnology facilitating the development of novel formulations. Furthermore, a broader acceptance of biological therapies has opened up new potential avenues for market expansion. However, challenges such as high costs, biosimilar competition, and stringent regulatory requirements pose significant barriers. To mitigate these obstacles, research is increasingly focusing on improving delivery mechanisms and reducing side effects through innovations like oral biologics and nanoparticle-delivered TNF inhibitors. The latest opportunities include harnessing advanced genetic research and AI-driven drug discovery to foster personalized medicine, enhancing treatment efficacy. Companies can also explore geographic expansion into emerging markets where the patient pool is expanding, but treatment options are limited. Moreover, bolstering patient education and fostering collaborations for health insurance coverage could enhance market penetration. Despite challenges from regulatory constraints and competitive pressures, the TNF inhibitors market offers substantial potential for growth through strategic innovation and a focus on unmet medical needs. By tailoring solutions that address specific customer and patient challenges, businesses can position themselves compellingly in this dynamic market landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 33.84 billion
Estimated Year [2024] USD 36.15 billion
Forecast Year [2030] USD 54.06 billion
CAGR (%) 6.92%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving TNF Inhibitors Market

The TNF Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of autoimmune diseases
    • Increasing healthcare expenditure and development in diagnostic techniques
  • Market Restraints
    • Adverse health effects and risk of infections associated with the use of TNF inhibitors
  • Market Opportunities
    • Advancements in biotechnology and development of new and improved TNF inhibitors
    • Growing application in treatment of diverse medical conditions such as cancer
  • Market Challenges
    • Availability of alternative treatment options for autoimmune disease

Porter's Five Forces: A Strategic Tool for Navigating the TNF Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the TNF Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the TNF Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the TNF Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the TNF Inhibitors Market

A detailed market share analysis in the TNF Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the TNF Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the TNF Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the TNF Inhibitors Market

A strategic analysis of the TNF Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the TNF Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkem Laboratories Ltd., Amgen Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Cadila Healthcare Ltd., Cipla Ltd., Dr Reddy's Laboratories Ltd., Emcure Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Janssen Pharmaceuticals, Johnson & Johnson Services, Inc., Lupin Ltd., Macleods Pharmaceuticals Pvt. Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Ranbaxy Laboratories Limited, Reliance Life Sciences, Roche Products India Pvt Ltd., Samsung Bioepis NL B.V., Sanofi S.A., Torrent Pharmaceuticals Ltd., and UCB Inc..

Market Segmentation & Coverage

This research report categorizes the TNF Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Biosimilars, Cimzia, Enbrel, Humira, Remicade, and Simponi/Simponi Aria.
  • Based on Application, market is studied across Ankylosing Spondylitis, Crohn's Disease, Hidradenitis Suppurativa, Juvenile Idiopathic Arthritis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, and Ulcerative Colitis.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of autoimmune diseases
      • 5.1.1.2. Increasing healthcare expenditure and development in diagnostic techniques
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse health effects and risk of infections associated with the use of TNF inhibitors
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in biotechnology and development of new and improved TNF inhibitors
      • 5.1.3.2. Growing application in treatment of diverse medical conditions such as cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative treatment options for autoimmune disease
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. TNF Inhibitors Market, by Product

  • 6.1. Introduction
  • 6.2. Biosimilars
  • 6.3. Cimzia
  • 6.4. Enbrel
  • 6.5. Humira
  • 6.6. Remicade
  • 6.7. Simponi/Simponi Aria

7. TNF Inhibitors Market, by Application

  • 7.1. Introduction
  • 7.2. Ankylosing Spondylitis
  • 7.3. Crohn's Disease
  • 7.4. Hidradenitis Suppurativa
  • 7.5. Juvenile Idiopathic Arthritis
  • 7.6. Psoriasis
  • 7.7. Psoriatic Arthritis
  • 7.8. Rheumatoid Arthritis
  • 7.9. Ulcerative Colitis

8. Americas TNF Inhibitors Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific TNF Inhibitors Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa TNF Inhibitors Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alkem Laboratories Ltd.
  • 3. Amgen Inc.
  • 4. Boehringer Ingelheim International GmbH
  • 5. Bristol Myers Squibb
  • 6. Cadila Healthcare Ltd.
  • 7. Cipla Ltd.
  • 8. Dr Reddy's Laboratories Ltd.
  • 9. Emcure Pharmaceuticals Ltd.
  • 10. Glenmark Pharmaceuticals Ltd.
  • 11. Intas Pharmaceuticals Ltd.
  • 12. Janssen Pharmaceuticals
  • 13. Johnson & Johnson Services, Inc.
  • 14. Lupin Ltd.
  • 15. Macleods Pharmaceuticals Pvt. Ltd.
  • 16. Merck KGaA
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Ranbaxy Laboratories Limited
  • 20. Reliance Life Sciences
  • 21. Roche Products India Pvt Ltd.
  • 22. Samsung Bioepis NL B.V.
  • 23. Sanofi S.A.
  • 24. Torrent Pharmaceuticals Ltd.
  • 25. UCB Inc.

LIST OF FIGURES

  • FIGURE 1. TNF INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. TNF INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TNF INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TNF INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES TNF INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES TNF INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. TNF INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. TNF INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TNF INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TNF INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TNF INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TNF INHIBITORS MARKET DYNAMICS
  • TABLE 7. GLOBAL TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TNF INHIBITORS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TNF INHIBITORS MARKET SIZE, BY CIMZIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TNF INHIBITORS MARKET SIZE, BY ENBREL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TNF INHIBITORS MARKET SIZE, BY HUMIRA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TNF INHIBITORS MARKET SIZE, BY REMICADE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TNF INHIBITORS MARKET SIZE, BY SIMPONI/SIMPONI ARIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TNF INHIBITORS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TNF INHIBITORS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TNF INHIBITORS MARKET SIZE, BY HIDRADENITIS SUPPURATIVA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TNF INHIBITORS MARKET SIZE, BY JUVENILE IDIOPATHIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL TNF INHIBITORS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL TNF INHIBITORS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL TNF INHIBITORS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL TNF INHIBITORS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES TNF INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. CHINA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. INDIA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. INDIA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. INDONESIA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. INDONESIA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. JAPAN TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. JAPAN TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. MALAYSIA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. MALAYSIA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. PHILIPPINES TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. PHILIPPINES TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. SINGAPORE TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. SINGAPORE TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. SOUTH KOREA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. SOUTH KOREA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. TAIWAN TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. TAIWAN TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. THAILAND TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. THAILAND TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. VIETNAM TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. VIETNAM TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. DENMARK TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. DENMARK TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. EGYPT TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. EGYPT TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. FINLAND TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. FINLAND TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. FRANCE TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. FRANCE TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. GERMANY TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. GERMANY TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ISRAEL TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. ISRAEL TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. ITALY TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. ITALY TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. NETHERLANDS TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. NETHERLANDS TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. NIGERIA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. NIGERIA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. NORWAY TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. NORWAY TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. POLAND TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. POLAND TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. QATAR TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. QATAR TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. RUSSIA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. RUSSIA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SAUDI ARABIA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. SAUDI ARABIA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH AFRICA TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH AFRICA TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. SPAIN TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. SPAIN TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SWEDEN TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. SWEDEN TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. SWITZERLAND TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. SWITZERLAND TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. TURKEY TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. TURKEY TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED ARAB EMIRATES TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED ARAB EMIRATES TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED KINGDOM TNF INHIBITORS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED KINGDOM TNF INHIBITORS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. TNF INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 110. TNF INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023